Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0014547 (focal epilepsy)
 1,627 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Peri-ictal water drinking (PIWD) has been reported as the action of drinking during or within two minutes of an electroclinical seizure. It is considered a peri-ictal vegetative symptom, evident both during childhood and adulthood epilepsy. The aim of this paper was to describe the clinical and electroencephalographic features of two new adult subjects suffering from symptomatic temporal lobe epilepsy with episodes of PIWD recorded by VIDEO-EEG and to review literature data in order to better define this peculiar event during seizures, a rare and probably underestimated semiological sign. To date, 51 cases with focal epilepsy and seizures associated with PIWD have been reported. All patients presented with temporal lobe epilepsy. All cases but one had symptomatic epilepsy. Most of the patients had an involvement of the right hemisphere. Water drinking was reported as an ictal sign in the majority of patients, and less frequently was reported as postictal. We believe that PIWD might be considered a rare automatic behaviour, like other automatisms. Automatisms are more frequently described in patients with temporal lobe epilepsy. PIWD was reported also to have lateralizing significance in the non-dominant temporal lobe, however, because of its rarity, this finding remains unclear.
Epileptic Disord 2015 Dec
PMID:Peri-ictal water drinking: a rare automatic behaviour in temporal lobe epilepsy. 2658 66

The DEPDC5 gene (OMIM #614191), mapped to 22q12.2-q12.3, encodes the DEP domain-containing protein 5. DEPDC5 has been associated with a variety of familial epilepsies, including familial focal epilepsy with variable foci, autosomal dominant nocturnal frontal lobe epilepsy, familial temporal lobe epilepsy, epileptic spasms, and cortical dysplasia.(1-4) Notably, DEPDC5 has never been linked to increased risk of sudden unexpected death in epilepsy (SUDEP). We report a family with epilepsy due to DEPDC5 mutation and 2 definite cases of SUDEP within this family.
Neurol Genet 2015 Dec
PMID:Two definite cases of sudden unexpected death in epilepsy in a family with a DEPDC5 mutation. 2706 65

Stereoelectroencephalography denotes the strategic placement of multiple depth electrodes for invasive localization of focal epilepsy in surgical patients. It differs significantly from the alternative subdural grid approach, in both conceptualization of partial epilepsy-as a 3-D distributed network, rather than as focal pathology with contiguous spread-and by the method of sampling used-which is sparse and directed rather than continuous over adjacent brain areas. The electrode implantation strategy in stereoelectroencephalography involves appreciation of these features, which are illustrated by four cases drawn from distinct electroclinical epilepsy syndromes.
J Clin Neurophysiol 2016 Dec
PMID:Stereo-EEG Implantation Strategy. 2791 43

Intracranial EEG has been in use for more than 50 years in the presurgical evaluation of patients with medically intractable focal epilepsy. The stereoelectroencephalography (SEEG) method has expanded very significantly over the last 5 years, in parallel with the increase in the number of complex cases (i.e., MRI-negative) being referred with medically intractable focal epilepsy to major epilepsy surgery centers. Some centers with extensive experience in subdural electrodes are indeed changing or have changed to SEEG as the principal exploration technique, which suggests that SEEG might offer specific benefits through its approach to accurately localizing the epileptogenic zone. However, interpretation of SEEG, which is a key step to its usefulness, may vary from one center to another. This may be due to different conceptual bases and the available expertise in each center. This heterogeneity in use of SEEG should be taken into account as it could contribute to erroneous conclusions and thus unfavorable outcome of epilepsy surgery. At present, there is a lack of guidelines for optimal SEEG use, although development of these is in progress. It remains challenging to translate SEEG interpretation into a practical approach to delineating surgical strategy. Identification of clear biomarkers will help in the definition of the epileptogenic zone and subsequent cortical resection. In addition, SEEG seems to be a unique tool for the in vivo investigation of human cerebral networks distributed over several lobes or sublobar structures, allowing a better understanding of their functioning.
J Clin Neurophysiol 2016 Dec
PMID:Stereoelectroencephalography: Interpretation. 2791 45

Drug-resistant epilepsy, not associated with acute brain complications or central nervous system leukaemic involvement, can develop in patients treated for acute lymphocytic leukaemia during childhood. It has been postulated that this rare complication may be due to CNS oncological treatment neurotoxicity, related to intrathecal drugs, such as methotrexate, and brain radiotherapy. We report four patients who developed drug-resistant epilepsy sometime after receiving treatment for acute lymphocytic leukaemia. All patients were female and received intrathecal methotrexate. One received additional intrathecal cytarabine, and two concomitant brain radiotherapy. Two developed Lennox-Gastaut type syndrome, one multifocal epilepsy, and one focal epilepsy related to a radiotherapy-induced cavernous angioma. The development of drug-resistant epilepsy after treatment for acute lymphocytic leukaemia is a rare complication that may vary, from focal epilepsy to an epileptic encephalopathy. This may appear even years after the treatment has finished and is most likely associated with treatment-related neurotoxicity.
Epileptic Disord 2016 Dec 01
PMID:Drug-resistant epilepsy after treatment for childhood acute lymphocytic leukaemia: from focal epilepsy to Lennox-Gastaut syndrome. 2793 21

Musicogenic epilepsy is a rare syndrome in which music triggers seizures. Affective network processing appears to play a key role in epileptogenesis. Many people with epilepsy suffer from comorbid affective disorders, the shared basis of which involves similar pathophysiologies, including deficiencies of serotonergic and noradrenergic function. Seizures and mood disorders may thus have reciprocal effects on one another, particularly in emotionally precipitated syndromes such as musicogenic epilepsy. I report a man with long-standing depression and anxiety who developed focal epilepsy that evolved into musicogenic seizures. His case suggests a pathophysiologic basis for this shared phenomenon.
Cogn Behav Neurol 2016 Dec
PMID:Musicogenic Epilepsy and Treatment of Affective Disorders: Case Report and Review of Pathogenesis. 2798 59

Utilizing the multicenter TSC (tuberous sclerosis complex) Natural History Database including 2034 subjects, this study aimed to identify predictors of drug-resistant epilepsy in TSC. Basic epilepsy data were available for 1965 individuals in the database. Supplemental data were further collected from 1546 of these subjects through directed site queries, addressing additional epilepsy characteristics including the presence of drug-resistant epilepsy, therapies trialed, and outcomes of specific therapies. Epilepsy was reported in 86.4% of individuals with TSC. Infantile spasms were reported in 45.2% of individuals and focal seizures were reported in 84.4% of individuals. In those with focal epilepsy, drug resistance was reported in 59.6%, with focal seizure onset prior to age 1 year (odds ratio [OR] 1.9, confidence interval [CI] 1.4-2.5, P < .001), infantile spasms (OR 2.0, CI 1.5-2.5, P < 0.001), and infantile spasms incompletely responsive to therapy (OR 47.6, CI 6.7-333.3, P < 0.001) being associated with an increased likelihood of drug resistance.
J Child Neurol 2017 Dec
PMID:Predictors of Drug-Resistant Epilepsy in Tuberous Sclerosis Complex. 2912 54

BACKGROUND Mesial temporal epilepsy (MTLE) is the most common type of focal epilepsy in adults, and is often drug-resistant. This study investigated the effects of aquaporins (AQP) inhibitor on multi-drug-resistant protein expression in an MTLE rat model. MATERIAL AND METHODS The MTLE rat model was established by injecting pilocarpine into rats. The MTLE rats were divided into an MTLE-6 h group, an MTLE-12 h group, and an MTLE-24 h group, together with a normal saline group (NS), to examine the AQP4 expression by using Western blot assay and immunohistochemistry assay. The other 18 MTLE model rats were used to observe the effects of the AQP4 inhibitor, acetazolamide, on the multi-drug-resistant protein 1 (MRP1) and P-glycoprotein (Pgp) by using Western blot and immunohistochemistry assays, respectively. RESULTS AQP4 expression was enhanced in hippocampal tissues of MTLE model rats compared to NS rats (P<0.05). More positively stained AQP4 was discovered in hippocampal tissues of MTLE model rats. AQP4 inhibitor significantly decreased multi-drug-resistant protein MRP1 and Pgp expression in the AQP4 inhibitor Interfere group and the AQP4 inhibitor Therapy group compared to the TMLE model group (P<0.05). CONCLUSIONS The present findings confirm that the AQP4 inhibitor, acetazolamide, effectively inhibits the multi-drug-resistant protein, MRP1, and Pgp, in the MTLE rat model.
Med Sci Monit 2017 Dec 08
PMID:Acetazolamide Suppresses Multi-Drug Resistance-Related Protein 1 and P-Glycoprotein Expression by Inhibiting Aquaporins Expression in a Mesial Temporal Epilepsy Rat Model. 2921 17

A wearable electroencephalogram (EEG) device for continuous monitoring of patients suffering from epilepsy would provide valuable information for the management of the disease. Currently no EEG setup is small and unobtrusive enough to be used in daily life. Recording behind the ear could prove to be a solution to a wearable EEG setup. This article examines the feasibility of recording epileptic EEG from behind the ear. It is achieved by comparison with scalp EEG recordings. Traditional scalp EEG and behind-the-ear EEG were simultaneously acquired from 12 patients with temporal, parietal, or occipital lobe epilepsy. Behind-the-ear EEG consisted of cross-head channels and unilateral channels. The analysis on Electrooculography (EOG) artifacts resulting from eye blinking showed that EOG artifacts were absent on cross-head channels and had significantly small amplitudes on unilateral channels. Temporal waveform and frequency content during seizures from behind-the-ear EEG visually resembled that from scalp EEG. Further, coherence analysis confirmed that behind-the-ear EEG acquired meaningful epileptic discharges similarly to scalp EEG. Moreover, automatic seizure detection based on support vector machine (SVM) showed that comparable seizure detection performance can be achieved using these two recordings. With scalp EEG, detection had a median sensitivity of 100% and a false detection rate of 1.14 per hour, while, with behind-the-ear EEG, it had a median sensitivity of 94.5% and a false detection rate of 0.52 per hour. These findings demonstrate the feasibility of detecting seizures from EEG recordings behind the ear for patients with focal epilepsy.
Sensors (Basel) 2017 Dec 23
PMID:Comparison between Scalp EEG and Behind-the-Ear EEG for Development of a Wearable Seizure Detection System for Patients with Focal Epilepsy. 2929 22

High-frequency oscillations (HFOs: 100 - 600 Hz) have been widely proposed as biomarkers of epileptic brain tissue. In addition, HFOs over a broader range of frequencies spanning 30 - 2000 Hz are potential biomarkers of both physiological and pathological brain processes. The majority of the results from humans with focal epilepsy have focused on HFOs recorded directly from the brain with intracranial EEG (iEEG) in the high gamma (65 - 100 Hz), ripple (100 - 250 Hz), and fast ripple (250 - 600 Hz) frequency ranges. These results are supplemented by reports of HFOs recorded with iEEG in the low gamma (30 - 65Hz) and very high frequency (500 - 2000 Hz) ranges. Visual detection of HFOs is laborious and limited by poor inter-rater agreement; and the need for accurate, reproducible automated HFOs detection is well recognized. In particular, the clinical translation of HFOs as a biomarker of the epileptogenic brain has been limited by the ability to reliably detect and accurately classify HFOs as physiological or pathological. Despite these challenges, there has been significant progress in the field, which is the subject of this review. Furthermore, we provide data and corresponding analytic code in an effort to promote reproducible research and accelerate clinical translation.
Curr Opin Biomed Eng 2017 Dec
PMID:Progress and Remaining Challenges in the Application of High Frequency Oscillations as Biomarkers of Epileptic Brain. 2953 41


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>